Tiffany Gould
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tiffany Gould has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Matthew D. Dun
University of Newcastle
2 shared publications Peter Pockney
2 shared publicationsAnya Rugendyke
1 shared publication- Brett Nixon
University of Newcastle
1 shared publication Daniel Zardawi
1 shared publicationDilharan D. Eliezer
1 shared publication
Latest Publications
- 1 February 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 246, 300-304
High-Risk Emergency Laparotomy in Australia: Comparing NELA, P-POSSUM, and ACS-NSQIP Calculators
- 1 February 2020
- Published by Elsevier in Journal of Surgical Research
- Vol. 246, 300-304
High-Risk Emergency Laparotomy in Australia: Comparing NELA, P-POSSUM, and ACS-NSQIP Calculators
- 1 April 2019
- Published by Elsevier in Journal of Surgical Research
- Vol. 236, 184-197
Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review
- 1 April 2019
- Published by Elsevier in Journal of Surgical Research
- Vol. 236, 184-197
Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review
- Open Access
- 6 February 2019
- Published by IntechOpen
Finding Needles in Haystacks: The Use of Quantitative Proteomics for the Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a common and treatable disease if diagnosed early. Current population screening programs are suboptimal, and consequently, there is a need for the development of new methodologies for early diagnosis of CRC. In the past 10 years, unprecedented technological advancements in the field of mass spectrometry (MS)-based proteomics have progressively increased the sophistication and utility of these investigations, leading to the draft mapping of the human proteome. These exciting studies have shaped our mechanistic understanding of the human genome and begun to provide us with a suite of novel biomarkers to predict the onset, progression and severity of many debilitating diseases. Thus, sophisticated MS workflows coupled with revolutionary protein quantification techniques hold promise for the field of MS-based plasma proteomics, particularly valuable in the context of early stage identification of curable CRC. However, within the last 40 years, no new plasma protein biomarkers of CRC have been translated into clinical practice. Here. we discuss the application of proteomic technologies within the field of CRC, highlighting contemporary MS-based plasma proteomic strategies that could be exploited to deliver on the promise of a panel of sensitive and specific plasma-based biomarkers with which to non-invasively detect early stage CRC.
- 6 February 2019
- Published by IntechOpen
Open AccessFinding Needles in Haystacks: The Use of Quantitative Proteomics for the Early Detection of Colorectal Cancer
Colorectal cancer (CRC) is a common and treatable disease if diagnosed early. Current population screening programs are suboptimal, and consequently, there is a need for the development of new methodologies for early diagnosis of CRC. In the past 10 years, unprecedented technological advancements in the field of mass spectrometry (MS)-based proteomics have progressively increased the sophistication and utility of these investigations, leading to the draft mapping of the human proteome. These exciting studies have shaped our mechanistic understanding of the human genome and begun to provide us with a suite of novel biomarkers to predict the onset, progression and severity of many debilitating diseases. Thus, sophisticated MS workflows coupled with revolutionary protein quantification techniques hold promise for the field of MS-based plasma proteomics, particularly valuable in the context of early stage identification of curable CRC. However, within the last 40 years, no new plasma protein biomarkers of CRC have been translated into clinical practice. Here. we discuss the application of proteomic technologies within the field of CRC, highlighting contemporary MS-based plasma proteomic strategies that could be exploited to deliver on the promise of a panel of sensitive and specific plasma-based biomarkers with which to non-invasively detect early stage CRC.